The long-term cardiovascular benefits of metabolic and bariatric surgery versus pharmacological therapies in patients with type 2 diabetes and obesity: a systematic review and meta-analysis.
Weight-loss surgery and newer GLP-1 drugs offer different long-term cardiovascular benefits, giving doctors real-world evidence to discuss surgical versus medical options.
This comparative retrospective cohort study characterizes long-term cardiovascular outcomes of metabolic bariatric surgery versus pharmacological therapies including GLP-1 receptor agonists in patients with T2D and obesity, providing real-world comparative effectiveness data as GLP-1 RAs have emerged as pharmacological alternatives to bariatric surgery for weight management. The findings address a critical clinical question as physicians increasingly choose between surgical and pharmacological approaches for this large, high-risk population.
What the study was
- Study design
- Comparative retrospective cohort study
- Population
- Patients with type 2 diabetes and obesity undergoing metabolic bariatric surgery versus receiving pharmacological therapies including GLP-1 receptor agonists
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
Why it surfaced
Comparative real-world effectiveness of bariatric surgery vs GLP-1 RA therapy for cardiovascular outcomes in T2D+obesity is highly relevant given rapid adoption of tirzepatide and semaglutide as alternatives to surgery.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.